Anti-ischemic effects of angiotensin-converting enzyme inhibition in hypertension

Journal of the American College of Cardiology

Volumn 38, Issue 4, 2001, Pages 1116-1122

  Prasad, Abhiram ^a   Mincemoyer, Rita ^a   Quyyumi, Arshed A ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENDOTHELIUM; FEMALE; FOREARM BLOOD FLOW; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; ST SEGMENT DEPRESSION; TREADMILL EXERCISE;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL AVAILABILITY; BRADYKININ; ENALAPRIL; EXERCISE TEST; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; VASCULAR RESISTANCE; VASODILATION;

EID: 0034811479     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(01)01506-6     Document Type: Article

References (25)

1. The obligatory role of the endothelial cells in the relaxation of arterial smooth muscle by acetylcholine
2. Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris: Reversibility by nitroglycerin
3. Atherosclerosis influences the vasomotor response of epicardial coronary arteries to exercise
4. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart
5. Role of endogenous bradykinin in human coronary vasomotor control
6. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway
7. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease
8. Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin-converting enzyme inhibition: A potential role of bradykinin
9. Effect of enalaprilat on nitric oxide activity in coronary artery disease
10. The insertion-deletion polymorphism of the ACE gene modulates the reversibility of endothelial dysfunction with converting enzyme inhibition
11. Effects of captopril on the physical work capacity of normotensive patients with stable-effort angina pectoris
12. Effects of captopril on myocardial perfusion in patients with coronary insufficiency: Evaluation by the exercise test and quantitative myocardial tomoscintigraphy using thallium-201
13. ACE inhibition with cilazapril improves myocardial perfusion to the ischemic regions during exercise: A pilot study
14. Long-term variation in myocardial ischemia during daily life in patients with stable coronary artery disease: Its relation to changes in the ischemic threshold
15. Does improvement of endothelial dysfunction improve myocardial ischemia? A double-blind comparison of parenteral D- or L-arginine
16. Repeated measures
17. The role of captopril as single therapy in hypertension and angina pectoris
18. Lack of reflex increase in myocardial sympathetic tone after captopril: Potential antianginal effect
19. The variable effect of angiotensin-converting enzyme inhibition on myocardial ischaemia in chronic stable angina
20. Coronary hemodynamic effects of angiotensin inhibition by captopril and teprotide in patients with congestive heart failure
21. Long-term anti-ischemic effects of angiotensin-converting enzyme inhibition in patients after myocardial infarction
22. Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUOVADIS Study). Quinapril On Vascular ACE and Determinants of Ischemia
23. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation
24. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans
25. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients